PT  - JOURNAL ARTICLE
AU  - Manning, Jessica
AU  - Zaidi, Irfan
AU  - Lon, Chanthap
AU  - Rosas, Luz Angela
AU  - Park, Jae-Keun
AU  - Ponce, Aiyana
AU  - Bohl, Jennifer
AU  - Chea, Sophana
AU  - Karkanitsa, Maria
AU  - Sreng, Sokunthea
AU  - Rekol, Huy
AU  - Chour, Char Meng
AU  - Esposito, Dominic
AU  - Taubenberger, Jeffery K.
AU  - Memoli, Matthew J.
AU  - Sadtler, Kaitlyn
AU  - Duffy, Patrick E.
AU  - Oliveira, Fabiano
TI  - Pre-pandemic SARS-CoV-2 serological reactivity in rural malaria-experienced Cambodians
AID  - 10.1101/2021.09.27.21264000
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.09.27.21264000
4099  - http://medrxiv.org/content/early/2021/09/28/2021.09.27.21264000.short
4100  - http://medrxiv.org/content/early/2021/09/28/2021.09.27.21264000.full
AB  - Greater Mekong inhabitants are exposed to pathogens, zoonotic and otherwise, that may influence SARS-CoV-2 seroreactivity. A pre-pandemic (2005 to 2011) serosurvey of from 528 malaria-experienced Cambodians demonstrated higher-than-expected (up to 13.8 %) positivity of non-neutralizing IgG to SARS-CoV-2 spike and RBD antigens. These findings have implications for interpreting large-scale serosurveys.Article Summary Line In the pre-COVID19 pandemic years of 2005 to 2011, malaria experienced Cambodians from rural settings had higher-than-expected seroreactivity to SARS-CoV-2 spike and receptor binding domain proteins.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis research was supported by the Intramural Research Program of the NIH, National Institute of Allergy and Infectious Diseases.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:These malaria research studies (NCT00341003, NCT00663546, NCT01350856) that collected de-identified, anonymized sera or plasma samples for future use, as done in this study published here, was approved by the Institutional Review Boards in the USA (National Institute of Allergy and Infectious Diseases Institutional Review Board) and in Cambodia (National Ethics Committee on Human Research; FWA #10451, IRB #3143).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData is available in appendix and also upon request.